Wednesday, October 31, 2018

SeeThruEquity Report Forecasts Earth Science Tech, Inc. (ETST) Sales of $7.1M by FY2020


  • In updated coverage report, SeeThruEquity projects that ETST will hit $2.2 million in sales for FY2019 based on its CBD product distribution and planned ‘As Seen On TV’ campaign
  • Direct response TV campaign seen raising awareness for ETST, which is eyeing growth for its line of hemp-derived products, planned pharmaceuticals and medical device introduction
  • A positive factor cited by the report was ETST’s uplisting to the OTCQB market; it also sees naming of celebrity Kevin Harrington as its direct response TV spokesperson as sales catalyst
Earth Science Tech, Inc. (OTCQB: ETST) is estimated by research firm SeeThruEquity, LLC to reach sales of $2.2 million in FY2019, then $7.1 million by FY2020, as the company expands its product line and media visibility in the growing legalized CBD market and fast-growing subcategory of hemp-based CBD (http://ibn.fm/FkAwY).

ETST has been moving quickly in several areas to position itself for growth. The company has announced that it is in talks with an organic CBD grower and processor for it to provide an exclusive business/supply agreement that will give ETST a consistent industrial hemp source. It has also announced that it is formulating a full spectrum cannabinoid (CBD) beverage through its provisional patent via its research with the University of Central Oklahoma focused on improving immune system functions (http://ibn.fm/D6gcm).

ETST is a biotech company based in Doral, Florida, marketing and developing CBD products, as well as dietary supplements, for the pharmaceutical and nutraceutical fields. The company is focused on the cannabidiol, pharmaceutical and nutraceutical sectors, as well as the development, through subsidiaries, of medical devices and research. ETST’s goal is to become a world leader in the CBD space.

Kevin Harrington, a TV celebrity, has been named spokesperson in the company’s direct response TV ads for its high-grade CBD oils. The “As Seen On TV” campaign will run for a period of 12 months and will feature 60-second ETST commercials aired in 10 regions and networks 300 times, it said (http://ibn.fm/cUrnC).

It is also moving ahead on the development of its Hygee medical device, finalizing an agreement with Groupe Opmedic Inc. and its Procrea Fertility Laboratories for lab services to detect sexually transmitted infections (STIs) in women using Hygee (http://ibn.fm/N0TZp).

On the CBD front, ETST is in discussions with an organic grower and processor for an exclusive business/supply relationship that offers the company its outdoor organic industrial hemp plants, mixing, extraction, bottling and packaging on an exclusive basis (http://ibn.fm/4FzWv).
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.

For more information, visit the company’s website at www.EarthScienceTech.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php


No comments: